Company intelligence / Profile preview

pacDNA

Cambridge, Massachusetts, USpitchbook.com ↗

Ownership: Private
Employees: ~1
Development stage: Preclinical

Overview

In preclinical models for cancer and rare genetic disorders, Brushield™ conjugates increase drug potency by up to 100x compared to state-of-the-art while suppressing side effects and immunogenicity[3]

Therapeutic areas: OncologyRare Diseases
Modalities: Oligonucleotide therapeutics
Industry: Biotech

Partnerships

Pursuing strategic partnerships within the pharmaceutical industry[2]

Beyond the preview

Go deeper on pacDNA.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on pacDNA.

Explore the full profile